Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2013

View Archived Issues

Pfizer's IMA-638 does not meet endpoints in phase IIa trial

Updated immunological results published from phase I evaluation of AE37 prostate cancer vaccine

Antibody DCBPR-01101 targets globo H for breast cancer treatment

Immunology data reported from phase IIb AllerT vaccine birch pollen allergy study

FDA approves subcutaneous formulation of Actemra for rheumatoid arthritis

Oxygen Biotherapeutics to complete development of levosimendan for fast track indication

AstraZeneca commences phase III program for selumetinib in NSCLC

Shionogi & Co. patents novel TRPV4 antagonists for pain

New EGFR inhibitors divulged by Chinese researchers

R-Pharm CJSC prepares new fusion proteins that bind to RANKL

Polaris submits IND application to begin phase I trials of ADI-PEG-20 in breast cancer

Novel coagulation factor Xa inhibitors synthesized at SciFluor Life Sciences

TherapeuticsMD's TX-12-004-HR estradiol VagiCap shown to improve objective measures of VVA

FDA grants orphan drug designation to Aduro's immunotherapy for pancreatic cancer

Phase I study evaluates Debio-0932 plus everolimus for advanced RCC

New model of Parkinson's disease created with proteasome inhibitor injection

Chemilia presents a new microtubule targeting/vascular disrupting agent

AstraZeneca to begin phase I study of AZD-6738

New PARP6 inhibitors identified for ovarian and breast cancer

Medivation and Astellas' phase III trial of enzalutamide in prostate cancer meets primary endpoints

Ferring initiates two phase III trials of infertility treatment candidate FE-999049

Amgen acquires Roche's rights to filgrastim and pegfilgrastim

Biocartis licenses test for colon cancer biomarker from Hospital del Mar

Cubist files NDA for tedizolid for treatment of serious skin infections

European approval of Gentium's Defitelio for severe veno-occlusive disease

Thomson Reuters and Orion Bionetworks to develop predictive models for multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...